Denmark to extend suspension of AstraZeneca COVID shot amid doubts

Denmark to extend suspension of Astra Zeneca COVID shot amid doubts

Denmark was among the first countries in Europe this month to suspend the use of the vaccine after reports of a small number of unusual cases of blood clots, registered both in Denmark and elsewhere.

"Analysis of AstraZeneca's safety database on tens of millions of records for Covid-19 Vaccine AstraZeneca did not show that these events occurred any more commonly than would be expected naturally in millions of people", a statement said.

Only seven per cent would decline regardless of which Covid-19 vaccine was on offer.

AstraZeneca had been counting on findings from a predominantly USA study of 32,000 people to help rebuild confidence in its shot, which is crucial to global efforts to end the coronavirus pandemic since it is cheap, easy to store and a pillar of the COVAX initiative aimed at bringing vaccines to low- and middle-income countries. Most European countries that had put the vaccine on hold resumed administering it after the European Medicines Agency said last week that it was safe. A peek at the full data won't come for at least another few weeks, once the Food and Drug Administration begins its own stringent review.

European Union attacks on AstraZeneca call into question its decision not to profit from its coronavirus vaccine, according to a leading member of the scientific team that delivered the breakthrough.

More women than men would say no, according to the survey.

AstraZeneca insisted that its COVID-19 vaccine provides strong protection even after counting additional illnesses in its US study, as the drugmaker responded to concerns raised by American officials in an unusually public rebuke that threatened to further erode confidence in the shot.

The uncertainty surrounding the vaccine seems to have had an effect on Danish confidence.

Approximately 150,000 people had already received AstraZeneca's shot in Denmark before it was suspended.

Officials in Ireland had said the decision to pause the use of the vaccine had been made on a precautionary principle.

"We believe it's good and necessary to have a bit more knowledge about how rare it is, and how we need to deal with it, and if it's possible to find risk factors behind it so that we can avoid [these events], because they are very, very serious and often fatal".

"Among other things, it's about understanding if there is a mechanical explanation as to whether this is caused by the vaccine and also if there are specific groups that one can rule out", she said.

Healthcare professionals are likewise told to report any suspected adverse reactions associated with the use of the vaccine in accordance with national reporting guidelines.

The World Health Organization has urged countries to continue administering the vaccine, arguing the benefits outweigh the risks.

Related:

Comments


Other news